Cosette Pharmaceuticals to Acquire Mayne Pharma for ~$430M
Shots:
- Cosette Pharmaceuticals to acquire Mayne Pharma Group for ~$430M, with shareholders receiving $4.71/share. Closing expected in Q2’25
- Acquisition will strengthen Cosette’s dermatology & women’s health business, adding 12 patent-protected products incl. Vyleesi, Intrarosa, Nextstellis, Annovera, Bijuva, Imvexxy, & Rhofade along with multiple pipeline candidates in its product line upon closing
- The combined entity will have 2 state of the art, FDA-approved manufacturing sites in Lincolnton, North Carolina, & Salisbury, South Australia, enhancing access to women's health therapies globally
Ref: Businesswire | Image: Mayne Pharma
Related News:- Novartis to Acquire Anthos Therapeutics for ~$3.1B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
